Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lilly’s Psoriasis Drug Taltz Set For Second Quarter Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Ixekizumab had a smooth FDA approval, with no advisory committee needed for the second member of the IL-17 inhibitor class.


Related Content

Lilly Management Reorg Brings In Shaw To Oversee Bio-Medicines
Valeant’s Brodalumab Delayed By FDA As REMS Is Negotiated
Novartis Pulling Out All The Stops To Amp Up Entresto Sales
Keeping Track: Approvals Aplenty As FDA Clears Taltz, Cinqair And Anthim
EU Committee Nod For Lilly's Ixekizumab In Psoriasis


Related Companies

Related Deals